Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veraxa Biotech AG - Ordinary Shares (NQ:VRXA)

1.340 -0.100 (-6.94%)
Streaming Delayed Price Updated: 12:50 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veraxa Biotech AG - Ordinary Shares

< Previous 1 2 Next >
BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
Via Investor Brand Network
News headline image
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activities 
From VERAXA Biotech GmbH
Via GlobeNewswire
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
Via Investor Brand Network
News headline image
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities 
From VERAXA Biotech GmbH
Via GlobeNewswire
VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’
Via Investor Brand Network
Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals
Via Investor Brand Network
InvestorNewsBreaks – Xlife Sciences AG (SIX: XLS) Shareholders Approve All Annual Meeting Proposals
Via Investor Brand Network
VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline
Via Investor Brand Network
BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline
Via Investor Brand Network
News headline image
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
Greater than 60% increase in laboratory space will strengthen R&D capabilities, facilitate acceleration toward clinical development, and increase ability to tap into Heidelberg’s world-class medical... 
From VERAXA Biotech GmbH
Via GlobeNewswire
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
Via Investor Brand Network
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
Via Investor Brand Network
BioMedNewsBreaks — VERAXA Biotech AG (NASDAQ: VRXA) Reports Proof-of-Concept Data for BiTAC-ADC Cancer Therapy Platform
Via Investor Brand Network
News headline image
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
BiTAC-ADC in vitro data, along with initial data from the most advanced BiTAC-TCE program recently presented at the American Association for Cancer Research (AACR) Annual Meeting, underpin the... 
From VERAXA Biotech GmbH
Via GlobeNewswire
InvestorNewsBreaks – Why VERAXA Biotech AG (NASDAQ: VRXA) Is ‘One to Watch’
Via Investor Brand Network
BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Completes Business Combination and Begins Trading on Nasdaq
Via Investor Brand Network
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.